Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...

Rigel Pharmaceuticals (RIGL) closed the last trading session at $17.35, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) recently released its preliminary financial results for the fourth quarter and fiscal year ended December 31, 2024, as outlined in an 8-K filing with the ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

For investors seeking deeper insights, InvestingPro offers exclusive analysis and 14 additional ProTips for Rigel Pharmaceuticals. The platform's comprehensive Fair Value analysis suggests the ...

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) said it expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 million for the same period of 2023. Rigel expects to ...

KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel Pharmaceuticals KFDA greenlights Tavalisse, a ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...